Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane) Followed by Vinorelbine for HER2 Overexpressing Early Stage Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2012
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary)
- Indications Early breast cancer
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Jun 2012 Official Title amended as reported by ClinicalTrials.gov.
- 13 Jun 2012 Actual patient number changed from 16 to 27 according to ClinicalTrials.gov.